Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
MUMBAI, Aug 17 (Reuters) - Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to make and market octreotide injection, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results